FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper
Authors:
- 1 October 2017
- journal article
- review article
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (1) , 3-10
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent diseaseAnnals of Oncology, 2013
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)International Journal of Gynecological Cancer, 2011
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆Gynecologic Oncology, 2007
- Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJournal of Clinical Oncology, 2006
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003